Struggling Biotech Company Faces 95% Market Value Drop and Implements Two Rounds of Layoffs in Four Months

In a challenging turn of events, KronosBio, a prominent biotech company listed on NASDAQ, has witnessed a staggering 95% decline in its market value. Compounded by setbacks in its core pipeline, the company has been forced to carry out two rounds of employee layoffs within a span of just four months. This article delves into the reasons behind this downturn and explores the company's efforts to navigate these challenging circumstances.

KronosBio recently announced its decision to implement a new round of layoffs, resulting in a 21% reduction in its workforce. This move aims to extend the company's cash runway until the latter half of 2026, while focusing its resources on the development of two promising oncology candidate drugs, KB-0742 and KB-9558, as well as its collaboration with Roche-owned Genentech. Notably, this marks the second wave of layoffs within approximately four months, following a prior reduction of 19% in the workforce.

The primary factor driving these layoffs is the unfavorable progress in clinical trials. In November 2022, KronosBio announced the termination of Phase III clinical trials for entospletinib, a spleen tyrosine kinase (SYK) inhibitor, in the treatment of NPM1-mutated acute myeloid leukemia (AML). The company shifted its focus to the development of lanraplenib, a next-generation SYK inhibitor, and KB-0742, a cyclin-dependent kinase 9 (CDK9) inhibitor. The decision to halt the trials was influenced by challenges in patient recruitment for NPM1-mutated AML, as well as the ongoing impact of the COVID-19 pandemic and delays in initiating clinical trials in Russia and Ukraine.

In addition to the pipeline setbacks, KronosBio has undertaken a series of cost-saving measures, including the dismissal of key executives. The company eliminated three crucial executive positions, including the Chief Medical Officer, Chief Scientific Officer, and Chief Operating Officer, along with the General Counsel. Furthermore, in August of the previous year, the Chief Financial Officer and Head of Corporate Development, Yasir Al-Wakeel, departed to pursue new opportunities as the CEO of a private biotech company. As a result, the company is now left with a leadership team that is almost entirely vacant.

Presently, KronosBio's focus is primarily centered on KB-0742, its sole remaining candidate drug in the clinical stage. The company's resources are concentrated on advancing the development of this CDK9 inhibitor. Data from the dose-escalation phase of the Phase I/II clinical trial of KB-0742 will be presented at the April meeting of the American Association for Cancer Research (AACR). The trial will recruit two patient cohorts: Cohort A, consisting of patients with MYC-amplified tumors such as triple-negative breast cancer, non-small cell lung cancer, and ovarian cancer; and Cohort B, comprising patients with transcriptional addiction cancers, including sarcoma, rhabdomyosarcoma, and small cell lung cancer. While CDK9 inhibitors hold promise as potential anti-cancer agents following the success of CDK4/6 inhibitors, there are currently no approved drugs in this class, and both KronosBio and AstraZeneca are in Phase II clinical trials, carrying inherent risks.

Furthermore, KronosBio is also advancing its p300KAT inhibitor, KB-9558, for the treatment of multiple myeloma through investigational new drug (IND) studies. The preclinical data for this project will be unveiled at the AACR meeting in April, with a potential initiation of first-in-human studies expected in 2025.

KronosBio, a once-promising biotech company, has faced significant challenges with a drastic decline in market value and setbacks in its core pipeline. The company's strategic response has included implementing two rounds of layoffs and refocusing its resources on key drug candidates. Despite the turbulent circumstances, KronosBio remains determined to forge ahead and regain its footing in the highly competitive biotech industry.